IS2722B - 1, 2, 3, 4- Tetrasetin indól til meðhöndlunar á öndunarfærasjúkdómum - Google Patents
1, 2, 3, 4- Tetrasetin indól til meðhöndlunar á öndunarfærasjúkdómumInfo
- Publication number
- IS2722B IS2722B IS8189A IS8189A IS2722B IS 2722 B IS2722 B IS 2722B IS 8189 A IS8189 A IS 8189A IS 8189 A IS8189 A IS 8189A IS 2722 B IS2722 B IS 2722B
- Authority
- IS
- Iceland
- Prior art keywords
- tetrasetin
- indole
- treatment
- respiratory diseases
- respiratory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0301569A SE0301569D0 (sv) | 2003-05-27 | 2003-05-27 | Novel compounds |
SE0302305A SE0302305D0 (sv) | 2003-05-27 | 2003-08-27 | Novel Compounds |
PCT/SE2004/000808 WO2004106302A1 (en) | 2003-05-27 | 2004-05-25 | Novel substituted 3-sulfur indoles |
Publications (2)
Publication Number | Publication Date |
---|---|
IS8189A IS8189A (is) | 2005-12-20 |
IS2722B true IS2722B (is) | 2011-03-15 |
Family
ID=33492578
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS8189A IS2722B (is) | 2003-05-27 | 2005-12-20 | 1, 2, 3, 4- Tetrasetin indól til meðhöndlunar á öndunarfærasjúkdómum |
IS8920A IS8920A (is) | 2003-05-27 | 2010-08-09 | 3-(Fenýl eða kínólyl)þíó- 1H-idnól-1-ediksýru afleður sem mótarar á virkni CRTh2 vitaka. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS8920A IS8920A (is) | 2003-05-27 | 2010-08-09 | 3-(Fenýl eða kínólyl)þíó- 1H-idnól-1-ediksýru afleður sem mótarar á virkni CRTh2 vitaka. |
Country Status (31)
Country | Link |
---|---|
US (4) | US7687535B2 (is) |
EP (3) | EP2281815B1 (is) |
JP (2) | JP4541361B2 (is) |
KR (3) | KR20110050754A (is) |
CN (2) | CN102391171A (is) |
AR (1) | AR044552A1 (is) |
AT (3) | ATE552243T1 (is) |
AU (1) | AU2004242624B2 (is) |
BR (1) | BRPI0410711B8 (is) |
CA (1) | CA2526866C (is) |
CO (1) | CO5630030A2 (is) |
CY (3) | CY1109104T1 (is) |
DE (2) | DE602004020072D1 (is) |
DK (3) | DK1656346T3 (is) |
ES (3) | ES2361485T3 (is) |
HK (3) | HK1090635A1 (is) |
HR (3) | HRP20090281T1 (is) |
IL (4) | IL171928A (is) |
IS (2) | IS2722B (is) |
MX (1) | MXPA05012680A (is) |
MY (1) | MY144483A (is) |
NO (1) | NO20056130L (is) |
NZ (1) | NZ543722A (is) |
PL (3) | PL2281815T3 (is) |
PT (3) | PT2025670E (is) |
RU (1) | RU2361860C2 (is) |
SE (2) | SE0301569D0 (is) |
SI (3) | SI2281815T1 (is) |
TW (2) | TW201024261A (is) |
WO (1) | WO2004106302A1 (is) |
ZA (1) | ZA200509598B (is) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
SE0301569D0 (sv) * | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
SE0302232D0 (sv) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
SE0303180D0 (sv) * | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
DE602005006539D1 (de) | 2004-03-11 | 2008-06-19 | Actelion Pharmaceuticals Ltd | Tetrahydropyridoindolderivate |
KR101329903B1 (ko) | 2004-12-27 | 2013-11-14 | 액테리온 파마슈티칼 리미티드 | Crth2 수용체 길항제로서의2,3,4,9-테트라하이드로-1h-카르바졸유도체 |
GB0500604D0 (en) * | 2005-01-13 | 2005-02-16 | Astrazeneca Ab | Novel process |
DOP2006000016A (es) * | 2005-01-26 | 2006-07-31 | Aventis Pharma Inc | 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2. |
ES2369714T3 (es) | 2005-04-21 | 2011-12-05 | Merck Serono Sa | Pirazina sulfonamidas 2,3 sustituidas como inhibidores de crth2. |
US8236963B2 (en) | 2005-05-24 | 2012-08-07 | Merck Serono Sa | Tricyclic spiro derivatives as CRTH2 modulators |
EP1911759A4 (en) | 2005-07-22 | 2010-07-21 | Shionogi & Co | AZAINDOL DERIVATIVE ANTAGONISTIC EFFECT ON PGD2 RECEPTOR |
WO2007010964A1 (ja) | 2005-07-22 | 2007-01-25 | Shionogi & Co., Ltd. | Pgd2受容体アンタゴニスト活性を有するインドール誘導体 |
EP1939175B1 (en) | 2005-09-27 | 2017-03-01 | Shionogi&Co., Ltd. | Sulfonamide derivative having pgd2 receptor antagonistic activity |
NZ566537A (en) * | 2005-09-30 | 2010-10-29 | Pulmagen Therapeutics Asthma L | Quinolines and their therapeutic use |
JP2009538289A (ja) * | 2006-05-26 | 2009-11-05 | アストラゼネカ・アクチエボラーグ | ビアリールまたはヘテロアリール置換インドール |
EP2037967B1 (en) | 2006-06-16 | 2016-12-07 | The Trustees Of The University Of Pennsylvania | Prostaglandin d2 receptor antagonists for treating androgenetic alopecia |
PL2046740T3 (pl) * | 2006-07-22 | 2012-10-31 | Oxagen Ltd | Związki o aktywności antagonisty CRTH2 |
PL2051962T3 (pl) | 2006-08-07 | 2012-03-30 | Actelion Pharmaceuticals Ltd | Pochodne kwasu (3-amino-1,2,3,4-tetrahydro-9h-karbazol-9-ilo)-octowego |
GB0702456D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
WO2008156780A1 (en) * | 2007-06-21 | 2008-12-24 | Actimis Pharmaceuticals, Inc. | Particulates of a crth2 antagonist |
EP2176240A1 (en) * | 2007-06-21 | 2010-04-21 | Actimis Pharmaceuticals, Inc., | Amine salts of a crth2 antagonist |
PT2229358E (pt) | 2007-12-14 | 2011-06-29 | Pulmagen Therapeutics Asthma Ltd | Indoles e sua utilização terapêutica |
US7750027B2 (en) * | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
US20110312945A1 (en) * | 2008-10-01 | 2011-12-22 | James Jia | Crth2 modulators |
JP2012517454A (ja) | 2009-02-12 | 2012-08-02 | メルク セローノ ソシエテ アノニム | フェノキシ酢酸誘導体 |
MX2012000229A (es) | 2009-07-06 | 2012-01-25 | Astrazeneca Ab | Intermediarios y procesos para preparar el acido 4-(acetilamino)-3-[(4-clorofenil)tio]-2-metil-1h-indol-1-acetico. |
GB0913345D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | New combination 802 |
WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
US9032565B2 (en) | 2009-12-16 | 2015-05-19 | Kohler Co. | Touchless faucet assembly and method of operation |
WO2011073662A1 (en) | 2009-12-17 | 2011-06-23 | Astrazeneca Ab | Combination of a benzoxazinone and a further agent for treating respiratory diseases |
SI2558447T1 (sl) | 2010-03-22 | 2015-01-30 | Actelion Pharmaceuticals Ltd. | Derivati 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-karbazola in njihova uporaba kot modulatorji prostaglandinskega receptorja d2 |
GB201021992D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
GB201021979D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | New compound |
PT2697223T (pt) | 2011-04-14 | 2016-10-14 | Actelion Pharmaceuticals Ltd | Derivados de ácido 7-(heteroaril-amino)-6,7,8,9-tetraidropirido[1,2-a]indolacético e utilização dos mesmos como moduladores do recetor d2 de prostaglandina |
CN104114169A (zh) | 2011-12-16 | 2014-10-22 | 阿托佩斯治疗有限公司 | 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物 |
EP2827952B1 (en) | 2012-03-21 | 2021-07-07 | The Trustees Of The University Of Pennsylvania | Composition for stimulating hair growth |
CA2886117C (en) * | 2012-10-05 | 2022-05-31 | Merck Sharp & Dohme Corp. | Indoline compounds and their use as aldosterone synthase inhibitors |
TWI634111B (zh) * | 2013-03-15 | 2018-09-01 | 普雷辛肯公司 | 雜環化合物及其用途 |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
AU2014268477A1 (en) * | 2013-05-24 | 2015-11-12 | The California Institute For Biomedical Research | Compounds for treatment of drug resistant and persistent tuberculosis |
CN106103435B (zh) | 2014-03-17 | 2018-11-16 | 爱杜西亚药品有限公司 | 氮杂吲哚乙酸衍生物及彼等作为前列腺素d2受体调节剂的用途 |
WO2015140701A1 (en) | 2014-03-18 | 2015-09-24 | Actelion Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
EP3328500B1 (en) | 2015-07-30 | 2023-04-12 | The Trustees of the University of Pennsylvania | Single nucleotide polymorphic alleles of human dp-2 gene for detection of susceptibility to hair growth inhibition by pgd2 antagonists |
CN108026093B (zh) | 2015-09-15 | 2021-11-16 | 爱杜西亚药品有限公司 | 结晶形式 |
JP2020536917A (ja) | 2017-10-13 | 2020-12-17 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼを調節するための化合物の固体形態 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE790679A (fr) | 1971-11-03 | 1973-04-27 | Ici Ltd | Derives de l'indole |
JPH0615542B2 (ja) | 1986-07-22 | 1994-03-02 | 吉富製薬株式会社 | ピラゾロピリジン化合物 |
US5095031A (en) | 1990-08-20 | 1992-03-10 | Abbott Laboratories | Indole derivatives which inhibit leukotriene biosynthesis |
WO1993005020A1 (en) | 1991-09-06 | 1993-03-18 | Merck & Co., Inc. | Indoles as inhibitors of hiv reverse transcriptase |
FR2692574B1 (fr) | 1992-06-23 | 1995-06-23 | Sanofi Elf | Derives hydroxy-4 benzenethio, leur preparation ainsi que leur utilisation pour la preparation de derives aminoalkoxybenzenesulfonyles. |
WO1994019321A1 (en) | 1993-02-24 | 1994-09-01 | Merck & Co., Inc. | Inhibitors of hiv reverse transcriptase |
US5486525A (en) | 1993-12-16 | 1996-01-23 | Abbott Laboratories | Platelet activating factor antagonists: imidazopyridine indoles |
US5567711A (en) | 1995-04-19 | 1996-10-22 | Abbott Laboratories | Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
IL125686A (en) | 1996-02-13 | 2002-11-10 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability |
WO1997032856A1 (en) | 1996-03-05 | 1997-09-12 | Zeneca Limited | 4-anilinoquinazoline derivatives |
TW472045B (en) | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
ZA987554B (en) | 1997-08-21 | 2000-02-21 | American Home Prod | Methods for the solid phase synthesis of substituted indole compounds. |
ZA9811672B (en) | 1997-12-19 | 2000-06-19 | Lilly Co Eli | Hypoglycemic imidazoline compounds. |
US6916841B2 (en) | 1998-02-25 | 2005-07-12 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
WO2000078761A1 (en) | 1999-06-23 | 2000-12-28 | Sepracor, Inc. | Indolyl-benzimidazole antibacterials, and methods of use thereof |
WO2001032621A1 (fr) | 1999-10-29 | 2001-05-10 | Wakunaga Pharmaceutical Co., Ltd. | Nouveaux derives d'indole, et medicaments contenant lesdits derives comme principe actif |
CZ301750B6 (cs) | 1999-12-24 | 2010-06-09 | Aventis Pharma Limited | Bicyklický pyrrolový derivát, jeho použití pri výrobe léciva, farmaceutická kompozice tento derivát obsahující a pro použití pri lécení |
IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
WO2002004434A1 (en) | 2000-07-07 | 2002-01-17 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as vascular damaging agents |
US6878522B2 (en) * | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
RU2003103603A (ru) | 2000-07-07 | 2004-08-20 | Энджиоджен Фармасьютикалз Лимитед (Gb) | Производные колхинола в качестве ингибиторов ангиогенеза |
JP4595182B2 (ja) * | 2000-09-07 | 2010-12-08 | ソニー株式会社 | 情報記録装置、情報再生装置、情報記録方法、情報再生方法、および情報記録媒体、並びにプログラム提供媒体 |
TWI317634B (en) | 2001-12-13 | 2009-12-01 | Nat Health Research Institutes | Aroyl indoles compounds |
RU2337909C2 (ru) | 2002-02-01 | 2008-11-10 | Ф.Хоффманн-Ля Рош Аг | Замещенные индолы и фармацевтическая композиция, обладающая агонистической активностью в отношении альфа-1a/l адренорецептора |
SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
WO2003097598A1 (fr) | 2002-05-16 | 2003-11-27 | Shionogi & Co., Ltd. | Composé comprenant un antagonisme du récepteur de pdg2 |
SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
TW200307542A (en) * | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
SE0202241D0 (sv) * | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
SE0202463D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
SE0301569D0 (sv) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
SE0302232D0 (sv) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
RU2006109108A (ru) | 2003-10-14 | 2007-11-20 | Оксаген Лимитед (GB) | Соединения, обладающие активностью антагонистов crth2 рецепторов |
SE0303180D0 (sv) | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
GB0500604D0 (en) | 2005-01-13 | 2005-02-16 | Astrazeneca Ab | Novel process |
GB2422831A (en) | 2005-02-04 | 2006-08-09 | Oxagen Ltd | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor |
JP2009538289A (ja) | 2006-05-26 | 2009-11-05 | アストラゼネカ・アクチエボラーグ | ビアリールまたはヘテロアリール置換インドール |
MX2008015501A (es) | 2006-06-08 | 2009-02-18 | Neurokey As | Uso de agonistas del receptor de canabinoide como farmacos inductores de hipotermia para el tratamiento de isquemia. |
WO2008000409A1 (en) | 2006-06-28 | 2008-01-03 | Sanofi-Aventis | New cxcr2 inhibitors |
-
2003
- 2003-05-27 SE SE0301569A patent/SE0301569D0/xx unknown
- 2003-08-27 SE SE0302305A patent/SE0302305D0/xx unknown
-
2004
- 2004-05-19 TW TW099109193A patent/TW201024261A/zh unknown
- 2004-05-19 TW TW093114113A patent/TWI328004B/zh not_active IP Right Cessation
- 2004-05-24 AR ARP040101792A patent/AR044552A1/es unknown
- 2004-05-25 NZ NZ543722A patent/NZ543722A/xx not_active IP Right Cessation
- 2004-05-25 AU AU2004242624A patent/AU2004242624B2/en not_active Ceased
- 2004-05-25 PL PL10180348T patent/PL2281815T3/pl unknown
- 2004-05-25 DE DE602004020072T patent/DE602004020072D1/de not_active Expired - Lifetime
- 2004-05-25 MY MYPI20041992A patent/MY144483A/en unknown
- 2004-05-25 WO PCT/SE2004/000808 patent/WO2004106302A1/en active Application Filing
- 2004-05-25 PT PT08165755T patent/PT2025670E/pt unknown
- 2004-05-25 EP EP10180348A patent/EP2281815B1/en not_active Expired - Lifetime
- 2004-05-25 CN CN2011102633202A patent/CN102391171A/zh active Pending
- 2004-05-25 BR BRPI0410711A patent/BRPI0410711B8/pt not_active IP Right Cessation
- 2004-05-25 SI SI200431874T patent/SI2281815T1/sl unknown
- 2004-05-25 DK DK04734774T patent/DK1656346T3/da active
- 2004-05-25 ES ES08165755T patent/ES2361485T3/es not_active Expired - Lifetime
- 2004-05-25 JP JP2006532212A patent/JP4541361B2/ja not_active Expired - Fee Related
- 2004-05-25 AT AT10180348T patent/ATE552243T1/de active
- 2004-05-25 EP EP08165755A patent/EP2025670B1/en not_active Expired - Lifetime
- 2004-05-25 PT PT10180348T patent/PT2281815E/pt unknown
- 2004-05-25 KR KR1020117009790A patent/KR20110050754A/ko not_active Application Discontinuation
- 2004-05-25 SI SI200431120T patent/SI1656346T1/sl unknown
- 2004-05-25 KR KR1020117009788A patent/KR101067535B1/ko not_active IP Right Cessation
- 2004-05-25 CA CA2526866A patent/CA2526866C/en not_active Expired - Fee Related
- 2004-05-25 ES ES10180348T patent/ES2382606T3/es not_active Expired - Lifetime
- 2004-05-25 PL PL04734774T patent/PL1656346T3/pl unknown
- 2004-05-25 CN CN2004800146027A patent/CN1795174B/zh not_active Expired - Fee Related
- 2004-05-25 ES ES04734774T patent/ES2322650T3/es not_active Expired - Lifetime
- 2004-05-25 KR KR1020057022513A patent/KR101067586B1/ko active IP Right Grant
- 2004-05-25 AT AT08165755T patent/ATE502010T1/de active
- 2004-05-25 PT PT04734774T patent/PT1656346E/pt unknown
- 2004-05-25 AT AT04734774T patent/ATE425965T1/de active
- 2004-05-25 PL PL08165755T patent/PL2025670T3/pl unknown
- 2004-05-25 US US10/558,228 patent/US7687535B2/en active Active
- 2004-05-25 DK DK08165755.3T patent/DK2025670T3/da active
- 2004-05-25 DE DE602004031894T patent/DE602004031894D1/de not_active Expired - Lifetime
- 2004-05-25 RU RU2005137403/04A patent/RU2361860C2/ru active
- 2004-05-25 SI SI200431669T patent/SI2025670T1/sl unknown
- 2004-05-25 MX MXPA05012680A patent/MXPA05012680A/es active IP Right Grant
- 2004-05-25 DK DK10180348.4T patent/DK2281815T3/da active
- 2004-05-25 EP EP04734774A patent/EP1656346B1/en not_active Expired - Lifetime
-
2005
- 2005-11-14 IL IL171928A patent/IL171928A/en not_active IP Right Cessation
- 2005-11-23 CO CO05118882A patent/CO5630030A2/es active IP Right Grant
- 2005-11-28 ZA ZA200509598A patent/ZA200509598B/en unknown
- 2005-12-20 IS IS8189A patent/IS2722B/is unknown
- 2005-12-22 NO NO20056130A patent/NO20056130L/no not_active Application Discontinuation
-
2006
- 2006-10-11 HK HK06111158.9A patent/HK1090635A1/xx not_active IP Right Cessation
-
2008
- 2008-10-23 IL IL194872A patent/IL194872A0/en unknown
-
2009
- 2009-03-04 US US12/397,618 patent/US20090163518A1/en not_active Abandoned
- 2009-05-15 HR HR20090281T patent/HRP20090281T1/xx unknown
- 2009-05-28 CY CY20091100564T patent/CY1109104T1/el unknown
- 2009-06-30 HK HK09105852.7A patent/HK1126773A1/xx not_active IP Right Cessation
- 2009-06-30 HK HK11107570.0A patent/HK1149563A1/xx not_active IP Right Cessation
-
2010
- 2010-03-31 JP JP2010082748A patent/JP2010155862A/ja active Pending
- 2010-08-09 IS IS8920A patent/IS8920A/is unknown
-
2011
- 2011-03-14 US US13/047,280 patent/US20110263614A1/en not_active Abandoned
- 2011-04-11 IL IL212265A patent/IL212265A0/en unknown
- 2011-04-14 IL IL212371A patent/IL212371A0/en unknown
- 2011-05-16 HR HR20110359T patent/HRP20110359T1/hr unknown
- 2011-05-16 CY CY20111100464T patent/CY1111469T1/el unknown
-
2012
- 2012-01-05 US US13/344,051 patent/US20120178764A1/en not_active Abandoned
- 2012-05-10 HR HRP20120390TT patent/HRP20120390T1/hr unknown
- 2012-05-29 CY CY20121100486T patent/CY1112853T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS2722B (is) | 1, 2, 3, 4- Tetrasetin indól til meðhöndlunar á öndunarfærasjúkdómum | |
IS2994B (is) | Fosfónöt, monofosfónamidöt, bisfosfónamidöt til meðhöndlunar á veirusjúkdómum | |
NO20053077D0 (no) | Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer. | |
DK1556342T3 (da) | Phenethanolaminderivat til behandling af respiratoriske sygdomme | |
AP2378A (en) | Sulfonamide derivatives for the treatment of diseases. | |
AP2359A (en) | Sulfonamide derivatives for the treatment of diseases. | |
IS7755A (is) | Aðferð við framleiðslu á (S,S)-cis-2-benshýdríl-3-bensýlamínókínuklídín | |
NO20053211D0 (no) | Forbindelser for behandling av metabolske forstyrrelser. | |
IS8142A (is) | Læknislyf gagnleg til meðferðar á verkjum | |
AP2005003283A0 (en) | Indole derivatives useful for the treatment os diseases | |
IS7691A (is) | Lyfjasamsetningar til að meðhöndla æxli | |
CY2014019I2 (el) | Παραγωγα φαιναιθανολαμινης για θεραπεια ασθενειων του αναπνευστικου | |
IS8398A (is) | Lyfjasamsetningar til að meðhöndla æxli | |
DK1656347T3 (da) | Substituerede indolderivater til farmaceutisk sammensætning til behandling af luftvejssygdomme | |
NO20033594L (no) | Fenetanolamin-derivater for behandling av luftveissykdommer | |
DE60325209D1 (de) | Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen | |
NO20052894D0 (no) | 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte | |
NO20055098D0 (no) | Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser | |
IS7137A (is) | Samsett meðferð til meðhöndlunar á krabbameini | |
NO20045554L (no) | Fremgangsmate for behandling av diabetes | |
DE602006003094D1 (de) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit | |
IS7444A (is) | Morfólínýl-þvagefna afleiður til notkunar við meðhöndlun á bólguvaldandi sjúkdómum | |
IS7163A (is) | Aðferðir til meðhöndlunar á lungnasjúkdómi | |
NO20054034D0 (no) | Fremgangsmate for behandling av hypotyroidisme. | |
AU2003303217A8 (en) | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases |